Tianjin Dexbio was selected as the ''Top 50 TEDA Technology'' enterprise

Recently, the 2017 Excellent Enterprises Conference of TEDA was held at the Yujiapu International Financial Conference Center. Tianjin Dexbio was invited to participate as a representative of the enterprise, and was awarded the "Top 50 TEDA Technology" enterprise and won the title of "Gazelle Enterprise".

"Top 50 TEDA Science and Technology" is the first selection after TEDA promulgated the "Ten TEDA Science and Technology Innovations", with the purpose of building a strong science and technology area and an innovative urban area. The companies and platform institutions selected for the first time in this round are comprehensively selected from the perspectives of technological originality, industrial influence, market value and scale, and are divided into 5  echelons, namely "unicorn companies", "leading companies", "Gazelle companies",with 10 companies in each echelon.

Since Tianjin Dexbio settled in the western area of the development zone in December 2011, it has focused on the construction and investment of scientific research platforms, and has also received strong support from the Tianjin Municipal Government and the Management Committee of the Development Zone. The company has successively undertaken the major science and technology projects of Tianjin, including "development of automatic blood group analyzer and series of test cards" and "development of platelet antibody detection kits and equipment for reducing platelet transfusion ineffectiveness" 

In 2012, the company was recognized as a "Science and Technology-based Small and Medium Enterprise", and in 2016 it was recognized as a Tianjin high-tech enterprise and a national high-tech enterprise. In recent years, we have increased investment in scientific research and continued to grow the scientific research team. By the end of 2017, our company has applied for 29 patents, and has made breakthroughs in the development and application of platelet matching detection, antibody screening, and immunohematology microfluidic detection technology.

Winning this honor is not only the development zone's high recognition of Tianjin Dexbio's scientific and technological innovation work in 2017, but also a higher requirement for the future development of Tianjin Dexbio. We will continue adhering to the concept of "To be perfect", with the strong support of the Tianjin Municipal Government and the Development Zone, continue to step up technological innovation, improve core competitiveness, contribute to the development of the Development Zone, and strive to achieve the corporate vision of "committed to developing into a leading company in the field of blood transfusion testing".